Efficacy and persistence between dimethyl fumarate, fingolimod, and ocrelizumab after natalizumab cessation

C. Zhu; T. Kalincik; D. Horakova; Z. Zhen; K. Buzzard; O. Skibina; R. Alroughani; G. Izquierdo; S. Eichau; J. Kuhle; F. Patti; F. Grand'Maison; S. Hodgkinson; P. Grammond; J. Lechner-Scott; E. Butler; A. Prat; M. Girard; P. Duquette; R. Macdonell; B. Weinstock-Guttman; S. Ozakbas; M. Slee; M. Jose Sa; V. Van Pesch; M. Barnett; B. Van Wijmeersch; O. Gerlach; J. Prevost; M. Terzi; C. Boz; G. Laureys; L. Van Hijfte; A. Kermode; J. Garber; B. Yamout; S. J. Khoury; V. Jokubaitis; M. Monif; D. Merlo; A. Van der Walt; H. Butzkueven

Efficacy and persistence between dimethyl fumarate, fingolimod, and ocrelizumab after natalizumab cessation

C. Zhu, T. Kalincik, D. Horakova, Z. Zhen, K. Buzzard, O. Skibina, R. Alroughani, G. Izquierdo, S. Eichau, J. Kuhle, F. Patti, F. Grand'Maison, S. Hodgkinson, P. Grammond, J. Lechner-Scott, E. Butler, A. Prat, M. Girard, P. Duquette, R. MacdonellB. Weinstock-Guttman, S. Ozakbas, M. Slee, M. Jose Sa, V. Van Pesch, M. Barnett, B. Van Wijmeersch, O. Gerlach, J. Prevost, M. Terzi, C. Boz, G. Laureys, L. Van Hijfte, A. Kermode, J. Garber, B. Yamout, S. J. Khoury, V. Jokubaitis, M. Monif, D. Merlo, A. Van der Walt, H. Butzkueven

Centre for Neuromuscular and Neurological Disorders (Perron Institute)

Research output: Contribution to journal › Abstract/Meeting Abstract › peer-review

Original language	English
Pages (from-to)	645-647
Number of pages	3
Journal	Multiple Sclerosis Journal
Volume	28
Issue number	3_SUPPL
Publication status	Published - Oct 2022
Event	38th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis - Amsterdam, Netherlands Duration: 26 Oct 2022 → 28 Oct 2022

Cite this

Zhu, C., Kalincik, T., Horakova, D., Zhen, Z., Buzzard, K., Skibina, O., Alroughani, R., Izquierdo, G., Eichau, S., Kuhle, J., Patti, F., Grand'Maison, F., Hodgkinson, S., Grammond, P., Lechner-Scott, J., Butler, E., Prat, A., Girard, M., Duquette, P., ... Butzkueven, H. (2022). Efficacy and persistence between dimethyl fumarate, fingolimod, and ocrelizumab after natalizumab cessation. Multiple Sclerosis Journal, 28(3_SUPPL), 645-647.

@article{6feb6c2dcccb4e2ab1420b2a3bfb91af,

title = "Efficacy and persistence between dimethyl fumarate, fingolimod, and ocrelizumab after natalizumab cessation",

author = "C. Zhu and T. Kalincik and D. Horakova and Z. Zhen and K. Buzzard and O. Skibina and R. Alroughani and G. Izquierdo and S. Eichau and J. Kuhle and F. Patti and F. Grand'Maison and S. Hodgkinson and P. Grammond and J. Lechner-Scott and E. Butler and A. Prat and M. Girard and P. Duquette and R. Macdonell and B. Weinstock-Guttman and S. Ozakbas and M. Slee and Sa, {M. Jose} and {Van Pesch}, V. and M. Barnett and {Van Wijmeersch}, B. and O. Gerlach and J. Prevost and M. Terzi and C. Boz and G. Laureys and {Van Hijfte}, L. and A. Kermode and J. Garber and B. Yamout and Khoury, {S. J.} and V. Jokubaitis and M. Monif and D. Merlo and {Van der Walt}, A. and H. Butzkueven",

year = "2022",

month = oct,

language = "English",

volume = "28",

pages = "645--647",

journal = "Multiple Sclerosis Journal",

issn = "1352-4585",

publisher = "SAGE Publications Ltd",

number = "3_SUPPL",

note = "38th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis ; Conference date: 26-10-2022 Through 28-10-2022",

}

Zhu, C, Kalincik, T, Horakova, D, Zhen, Z, Buzzard, K, Skibina, O, Alroughani, R, Izquierdo, G, Eichau, S, Kuhle, J, Patti, F, Grand'Maison, F, Hodgkinson, S, Grammond, P, Lechner-Scott, J, Butler, E, Prat, A, Girard, M, Duquette, P, Macdonell, R, Weinstock-Guttman, B, Ozakbas, S, Slee, M, Sa, MJ, Van Pesch, V, Barnett, M, Van Wijmeersch, B, Gerlach, O, Prevost, J, Terzi, M, Boz, C, Laureys, G, Van Hijfte, L, Kermode, A, Garber, J, Yamout, B, Khoury, SJ, Jokubaitis, V, Monif, M, Merlo, D, Van der Walt, A & Butzkueven, H 2022, 'Efficacy and persistence between dimethyl fumarate, fingolimod, and ocrelizumab after natalizumab cessation', Multiple Sclerosis Journal, vol. 28, no. 3_SUPPL, pp. 645-647.

TY - JOUR

T1 - Efficacy and persistence between dimethyl fumarate, fingolimod, and ocrelizumab after natalizumab cessation

AU - Zhu, C.

AU - Kalincik, T.

AU - Horakova, D.

AU - Zhen, Z.

AU - Buzzard, K.

AU - Skibina, O.

AU - Alroughani, R.

AU - Izquierdo, G.

AU - Eichau, S.

AU - Kuhle, J.

AU - Patti, F.

AU - Grand'Maison, F.

AU - Hodgkinson, S.

AU - Grammond, P.

AU - Lechner-Scott, J.

AU - Butler, E.

AU - Prat, A.

AU - Girard, M.

AU - Duquette, P.

AU - Macdonell, R.

AU - Weinstock-Guttman, B.

AU - Ozakbas, S.

AU - Slee, M.

AU - Sa, M. Jose

AU - Van Pesch, V.

AU - Barnett, M.

AU - Van Wijmeersch, B.

AU - Gerlach, O.

AU - Prevost, J.

AU - Terzi, M.

AU - Boz, C.

AU - Laureys, G.

AU - Van Hijfte, L.

AU - Kermode, A.

AU - Garber, J.

AU - Yamout, B.

AU - Khoury, S. J.

AU - Jokubaitis, V.

AU - Monif, M.

AU - Merlo, D.

AU - Van der Walt, A.

AU - Butzkueven, H.

PY - 2022/10

Y1 - 2022/10

M3 - Abstract/Meeting Abstract

SN - 1352-4585

VL - 28

SP - 645

EP - 647

JO - Multiple Sclerosis Journal

JF - Multiple Sclerosis Journal

IS - 3_SUPPL

T2 - 38th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis

Y2 - 26 October 2022 through 28 October 2022

ER -